Medical Treatment of Central Giant Cell Lesions of the Jaws

Authors

  • Alaa S. Mohmed Lecturer of oral and maxillofacial surgery at faculty of dentistry, University of Karary,Sudan 2:Assistant professor of oral & maxillofacial surgery, Faculty of Dentistry, University of Khartoum, Sudan
  • Yousif I. Eltohami Assistant professor of oral & maxillofacial surgery, faculty of dentistry,University of Khartoum, Sudan
  • Ahmed M. Suleiman Professor of oral & maxillofacial surgery, Faculty of Dentistry, University of Khartoum, Sudan

DOI:

https://doi.org/10.37591/rrjod.v9i3.631

Abstract

 

Central giant cell lesions (CGCLs) of the jaw are benign, non-neoplastic intraosseous proliferative lesions of an osteoclastic origin and an unknown etiology; their conventional treatment is surgical enculeation and curettage with a reported recurrence rate of 15–20%.

Because of the inherit problems with the surgical approach (recurrence rate, surgical defect, disfigurement, loss of function, and GA associated morbidity) alternative medical treatments have been proposed over the last 15 years with promising results; these options include intralesional steroid injections, interferon alpha, systemic steroids, calcitonin, bisphosphonate, denosumab, or combination therapy.

 

Keywords: central giant cell lesions (CGCLs) of the jaw, medical management, steroid injections, interferon alpha, calcitonin


Cite this Article

Mohmed AS, Eltohami YI, Suleiman AM. Medical treatment of central giant cell lesions of the jaws. Research & Reviews: A Journal of Dentistry. 2018; 9(3): 1–6p.


Downloads

Published

2019-01-25

Issue

Vol. 9 No. 3 (2018)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.